LP-533401 hydrochloride is primarily researched for its potential therapeutic applications, particularly in the treatment of fibrotic diseases and metabolic disorders. Its mechanism of action involves the inhibition of lysyl oxidase-like 2 (LOXL2), an enzyme that plays a critical role in the cross-linking of collagen and elastin, processes that contribute to tissue fibrosis. By targeting LOXL2, LP-533401 hydrochloride shows promise in reducing fibrosis in organs such as the liver, lungs, and kidneys, making it a candidate for treating conditions like liver cirrhosis, pulmonary fibrosis, and chronic kidney disease. Additionally, its ability to modulate extracellular matrix remodeling has sparked interest in its use for cancer therapy, as fibrosis is often associated with tumor progression and metastasis. Ongoing studies are also exploring its potential in addressing metabolic syndromes, given its influence on tissue stiffness and cellular signaling pathways.